Pfizer于2025年11月13日完成了对Metsera的1 000美元采购,以提升其肥胖药物管道。 Pfizer completed its $10B acquisition of Metsera on Nov. 13, 2025, to boost its obesity drug pipeline.

Pfizer已经完成了对Metsera的收购,Metsera是一家发展肥胖治疗的美国生物技术公司,这笔交易价值高达100亿美元。 Pfizer has completed its acquisition of Metsera, a U.S. biotech firm developing obesity treatments, in a deal worth up to $10 billion. 购买于2025年11月13日完成,包括每个现金份额65.60美元和与药物发展里程碑挂钩的以业绩为基础的付款20.65美元。 The purchase, finalized on November 13, 2025, includes $65.60 per share in cash and up to $20.65 in performance-based payments tied to drug development milestones. 此举是在与诺和诺德展开竞争性竞购战之后进行的，并加强了辉瑞在不断增长的减肥药市场中的地位。 The move follows a competitive bidding war with Novo Nordisk and strengthens Pfizer’s position in the growing weight-loss drug market. Metsera的主要候选人MET-097i在试验中显示出有希望的结果,参与者体重损失高达14.1%,预计将进入后期测试阶段。 Metsera’s lead candidate, MET-097i, showed promising results in trials, with participants losing up to 14.1% of body weight, and is expected to enter late-stage testing. Pfizer旨在利用其全球基础设施推进该药物,目标是2028-2029年的发射。 Pfizer aims to leverage its global infrastructure to advance the drug, targeting a 2028–2029 launch. 此次收购支持辉瑞的多元化战略，超越 Eliquis 和 Ibrance 等药物收入下降。 The acquisition supports Pfizer’s strategy to diversify beyond declining revenue from drugs like Eliquis and Ibrance.